Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade

Liang Zhao,Yizhen Pang,Yangfan Zhou,Jianhao Chen,Hao Fu,Wei Guo,Weizhi Xu,Xin Xue,Guoqiang Su,Long Sun,Hua Wu,Jingjing Zhang,Zhanxiang Wang,Qin Lin,Xiaoyuan Chen,Haojun Chen
DOI: https://doi.org/10.1038/s41392-024-01853-w
IF: 39.3
2024-06-03
Signal Transduction and Targeted Therapy
Abstract:Radiotherapy combined with immune checkpoint blockade holds great promise for synergistic antitumor efficacy. Targeted radionuclide therapy delivers radiation directly to tumor sites. LNC1004 is a fibroblast activation protein (FAP)-targeting radiopharmaceutical, conjugated with the albumin binder Evans Blue, which has demonstrated enhanced tumor uptake and retention in previous preclinical and clinical studies. Herein, we demonstrate that 68 Ga/ 177 Lu-labeled LNC1004 exhibits increased uptake and prolonged retention in MC38/NIH3T3-FAP and CT26/NIH3T3-FAP tumor xenografts. Radionuclide therapy with 177 Lu-LNC1004 induced a transient upregulation of PD-L1 expression in tumor cells. The combination of 177 Lu-LNC1004 and anti-PD-L1 immunotherapy led to complete eradication of all tumors in MC38/NIH3T3-FAP tumor-bearing mice, with mice showing 100% tumor rejection upon rechallenge. Immunohistochemistry, single-cell RNA sequencing (scRNA-seq), and TCR sequencing revealed that combination therapy reprogrammed the tumor microenvironment in mice to foster antitumor immunity by suppressing malignant progression and increasing cell-to-cell communication, CD8 + T-cell activation and expansion, M1 macrophage counts, antitumor activity of neutrophils, and T-cell receptor diversity. A preliminary clinical study demonstrated that 177 Lu-LNC1004 was well-tolerated and effective in patients with refractory cancers. Further, scRNA-seq of peripheral blood mononuclear cells underscored the importance of addressing immune evasion through immune checkpoint blockade treatment. This was emphasized by the observed increase in antigen processing and presentation juxtaposed with T cell inactivation. In conclusion, our data supported the efficacy of immunotherapy combined with 177 Lu-LNC1004 for cancer patients with FAP-positive tumors.
biochemistry & molecular biology,cell biology
What problem does this paper attempt to address?
The paper aims to address the following issues: 1. **Enhancing Anti-Tumor Efficacy**: The study explores how to enhance anti-tumor effects by combining radioligand therapy (using the radiopharmaceutical 177Lu-LNC1004 targeting fibroblast activation protein FAP) with immune checkpoint blockade therapy (using anti-PD-L1 antibodies). 2. **Improving Tumor Microenvironment**: The research found that the combination therapy can reprogram the tumor microenvironment in mice, promoting anti-tumor immune responses. This includes increasing intercellular communication, activating CD8+ T cells, expanding the number of M1 macrophages, enhancing the anti-tumor activity of neutrophils, and increasing T cell receptor diversity. 3. **Validating Clinical Efficacy**: Preliminary clinical studies indicate that 177Lu-LNC1004 shows good tolerance and efficacy in patients with refractory cancers. In summary, the paper primarily focuses on how to enhance anti-tumor efficacy through the combination of radioligand therapy and immune checkpoint blockade therapy, and explores its potential mechanisms.